Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9303811 | 0.78 | MIF (0.44) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL2867417 | 0.78 | MIF (0.44) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL8733281 | 0.76 | MIF (0.43) | MIFTAAR1KDM4EADRA2AADRA2C | |
| Isopropylbenzene SCHEMBL28152323 | 0.76 | MIF (0.43) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL1453760 | 0.75 | MIF (0.39) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL97552 | 0.74 | MIF (0.41) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL198507 | 0.74 | TSHR (0.52) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL8711629 | 0.74 | MIF (0.41) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL7039581 | 0.74 | TSHR (0.52) | MIFTAAR1KDM4EADRA2AADRA2C | |
| SCHEMBL3151083 | 0.74 | MIF (0.41) | MIFTAAR1KDM4EADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137092-A1 | Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis | EMERALD HEALTH PHARMACEUTICALS INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4099993-A1 | COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF CARDIAC, PULMONARY, DERMAL, AND RENAL FIBROSIS | Emerald Health Pharmaceuticals Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220184003-A1 | Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2) | EMERALD HEALTH PHARMACEUTICALS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | FIRMENICH INCORPORATED (US) | 2022-03-08 | — | — | US | disclosed |
| CN-113544117-A | Formulations of cannabidiol derivatives and their use as cannabinoid type 2 receptors (CB)２) Use of the modulators of | 埃默拉尔德健康制药公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021159059-A1 | COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF CARDIAC, PULMONARY, DERMAL, AND RENAL FIBROSIS | EMERALD HEALTH PHARMACEUTICALS INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| CN-109195979-B | Catalyst for the hydroformylation of olefins and use thereof | 柏林工业大学 | 2021-06-15 | — | — | CN | disclosed |
| US-10947335-B2 | Triazine-precondensate-aldehyde condensation products and method for obtaining the same | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2021-03-16 | — | — | US | disclosed |
| US-10941123-B2 | Triazine precondensate and method for obtaining the same | BOREALIS AGROLINZ MELAMINE GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| EP-3478668-B1 | NOVEL TRIAZINE PRECONDENSATE AND METHOD FOR OBTAINING THE SAME | BOREALIS AGROLINZ MELAMINE (AT) | 2021-02-24 | — | — | EP | disclosed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | disclosed |
| CN-1022685-C | Hydrofluorene derivatives | OTSUKA PHARMA CO LTD (JP) | 1993-11-10 | — | — | CN | disclosed |
| EP-0148883-B1 | ALLOPURINOL PRODRUGS | A/S GEA Farmaceutisk Fabrik (DK) | 1990-02-14 | — | — | EP | disclosed |
| US-4742073-A | ANTIGLAUCOMA | BUNDGAARD HANS (DK) | 1988-05-03 | — | — | US | disclosed |
| US-4694006-A | Acyl- or acyloxymethyl-allopurinol prodrugs | A/S GEA (DK) | 1987-09-15 | — | — | US | disclosed |
| EP-0106541-A2 | Pilocarpine prodrugs | Bundgaard, Hans (DK) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947335-B2 | Triazine-precondensate-aldehyde condensation products and method for obtaining the same | ALDH5A1, DERA, ALDOA | MIF 3781/4885TAAR1 554/4885KDM4E 2563/4885 |
| US-20220184003-A1 | Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2) | CNR2, CNR1, MAG | MIF 4625/4885TAAR1 470/4885KDM4E 3135/4885 |
| US-10941123-B2 | Triazine precondensate and method for obtaining the same | NDUFS5, CBR3, MT-ND5 | MIF 4748/4885TAAR1 77/4885KDM4E 2893/4885 |
| US-20230137092-A1 | Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis | FABP3, JUP, DSP | MIF 4120/4885TAAR1 1440/4885KDM4E 3440/4885 |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | TAS2R40, TAS1R2, TAS1R1 | MIF 3416/4885TAAR1 145/4885KDM4E 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.